Exposure–Response Analyses of Anaplastic Lymphoma Kinase Inhibitors Crizotinib and Alectinib in Non‐Small Cell Lung Cancer Patients

Crizotinib and alectinib are anaplastic lymphoma kinase (ALK)‐inhibitors indicated for the treatment of ALK‐positive metastatic non‐small cell lung cancer (NSCLC). At the currently used fixed doses, interindividual variability in exposure is high. The aim of this study was to investigate whether min...

Descripción completa

Detalles Bibliográficos
Autores principales: Groenland, Stefanie L., Geel, Dieuwertje R., Janssen, Julie M., de Vries, Niels, Rosing, Hilde, Beijnen, Jos H., Burgers, Jacobus A., Smit, Egbert F., Huitema, Alwin D.R., Steeghs, Neeltje
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7891593/
https://www.ncbi.nlm.nih.gov/pubmed/32686074
http://dx.doi.org/10.1002/cpt.1989

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7891593/
https://www.ncbi.nlm.nih.gov/pubmed/32686074
http://dx.doi.org/10.1002/cpt.1989

Ejemplares similares